First demonstration of a novel nerve-targeting fluorophore in a cohort of ex vivo human tissues.

First demonstration of a novel nerve-targeting fluorophore in a cohort of ex vivo human tissues.
复制标题

首次在一组离体人体组织中展示新型神经靶向荧光团。

DOI:
10.1117/12.2650748
复制
发表时间:
2023
期刊:
Proceedings of SPIE--the International Society for Optical Engineering
影响因子:
--
通讯作者:
Henderson,EricR
Henderson,EricR
中科院分区:
--
文献类型:
--
作者:
Hebert,KendraA;Bateman,Logan;Parker,Dylan;Nunziata,Jenna;Paydarfar,JosephA;Hong,Jennifer;Kerr,DarcyA;Zanazzi,GeorgeJ;Barth,ConnorW;Wang,Lei;Gibbs,SummerL;Henderson,EricR

文献摘要

相似文献

医源性神经损伤是所有外科专科常见的并发症。手术中更好的神经可视化和识别将改善预后并减少神经损伤。俄勒冈健康与科学大学的吉布斯实验室开发了一个近红外、神经特异性荧光团库,用于在手术中突出神经,并帮助外科医生识别和可视化神经;目前的主要代理是LGW16-03。在本研究之前,LGW16-03的检测仅限于动物模型;因此,LGW16-03在人体组织中的作用尚不清楚。为了将LGW16-03推向临床,我们试图在一组患者的离体人体组织中测试这种目前的铅剂,并确定给药途径是否会影响LGW16-03神经和邻近背景组织(肌肉和脂肪)之间的荧光对比。LGW16-03通过两种策略应用于下肢截肢的离体人体组织:(1)使用我们的首个荧光团测试模型系统给药,(2)局部应用荧光团。结果显示局部用药与全身用药无统计学差异。然而,这些发现需要在体内进行人体验证。
Iatrogenic nerve injury is a common complication across all surgical specialties. Better nerve visualization and identification during surgery will improve outcomes and reduce nerve injuries. The Gibbs Laboratory at Oregon Health and Science University has developed a library of near-infrared, nerve-specific fluorophores to highlight nerves intraoperatively and aid surgeons in nerve identification and visualization; the current lead agent is LGW16–03. Prior to this study, testing of LGW16–03 was restricted to animal models; therefore, it was unknown how LGW16–03 performs in human tissue. To advance LGW16–03 to clinic, we sought to test this current lead agent in ex vivo human tissues from a cohort of patients and determine if the route of administration affects LGW16–03 fluorescence contrast between nerves and adjacent background tissues (muscle and adipose). LGW16–03 was applied to ex vivo human tissue from lower limb amputations via two strategies: (1) systemic administration of the fluorophore using our first-in-kind model for fluorophore testing, and (2) topical application of the fluorophore. Results showed no statistical difference between topical and systemic administration. However, in vivo human validation of these findings is required.